Indolent B-Cell Non-Hodgkin Lymphoma
Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BioInvent InternationalBI-1206
Clinical Trials (1)
Total enrollment: 140 patients across 1 trials
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Start: May 2018Est. completion: Sep 2026140 patients
Phase 1/2Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
4m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
4m ago
Office Administrator
SystImmune
4m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
15m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
18m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
18m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 140 patients
1 companies competing in this space